JP Morgan Chase
OMED

JP Morgan Chase’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

JP Morgan Chase’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,500
Closed -$13K – 6011
2018
Q2 		$13K Sell
5,500
-6,178
-53% -$18K ﹤0.01% 5355
2018
Q1 		$37K Buy
+11,678
New +$32.2K ﹤0.01% 4916
2017
Q3 		– Sell
-83,345
Closed -$277K – 5428
2017
Q2 		$277K Buy
83,345
+77,886
+1,427% +$323K ﹤0.01% 3904
2017
Q1 		$50K Hold
5,459
– – ﹤0.01% 4531
2016
Q4 		$42K Sell
5,459
-222
-4% -$2.04K ﹤0.01% 4590
2016
Q3 		$65K Sell
5,681
-379
-6% -$4.41K ﹤0.01% 3976
2016
Q2 		$74K Sell
6,060
-38,182
-86% -$463K ﹤0.01% 3943
2016
Q1 		$447K Sell
44,242
-94,936
-68% -$1.11M ﹤0.01% 3385
2015
Q4 		$3.14M Buy
+139,178
New +$2.85M ﹤0.01% 2502
2015
Q3 		– Sell
-112,283
Closed -$2.53M – 4338
2015
Q2 		$2.53M Buy
112,283
+29,036
+35% +$716K ﹤0.01% 2772
2015
Q1 		$2.15M Buy
+83,247
New +$2.11M ﹤0.01% 2826
2014
Q4 		– Sell
-43,785
Closed -$829K – 4574
2014
Q3 		$829K Buy
43,785
+21,071
+93% +$423K ﹤0.01% 3437
2014
Q2 		$529K Buy
+22,714
New +$561K ﹤0.01% 3093
2013
Q4 		– Sell
-99,775
Closed -$1.53M – 4508
2013
Q3 		$1.53M Buy
+99,775
New +$1.85M ﹤0.01% 2982

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

JP Morgan Chase's OMED Position: Q3 2018 in Review

JP Morgan Chase sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2018, closing a stake of 5,500 shares — an estimated $13K sold.

JP Morgan Chase first reported a position in OMED in Q3 2013 and held it in 14 quarters. The position peaked at $3.14M in Q4 2015. 54 funds tracked by Wall St. Rank hold OMED as of Q3 2018.

  • JP Morgan Chase reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • JP Morgan Chase sold 5,500 OncoMed Pharmaceuticals, Inc. shares in Q3 2018, an estimated $13K.
  • JP Morgan Chase first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 14 quarters.
  • JP Morgan Chase's OncoMed Pharmaceuticals, Inc. position peaked at $3.14M in Q4 2015.
  • 54 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2018.

Based on JP Morgan Chase's 13F filing for Q3 2018, filed 7 Nov 2018.